MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$226K
Free Cash flow
$13,652K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from short-term marketa...
Depreciation and amortization
Accrued interest
Others
Negative Cash Flow Breakdown
Purchases of short-term marketab...
Cost of sales
Selling expense
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net sales
70,382
66,551
64,453
185,149
Cost of sales
19,618
18,155
18,263
52,800
Gross profit
50,764
48,396
46,190
132,349
Selling expense
12,845
12,800
12,162
37,272
Marketing expense
1,563
1,715
1,272
3,758
Administrative expense
7,526
7,963
6,975
21,268
Finance expense
2,647
3,184
2,718
8,322
Management information systems expense
937
899
698
2,043
Research and development expense
1,472
1,423
1,069
2,970
Process engineering expense
1,338
1,002
802
1,828
Regulatory and clinical expense
2,037
1,635
1,662
5,808
Restructuring expense
-
-
0
-
Other (income) expense, net
-3,349
-2,096
-3,250
-6,928
Net income
17,050
15,679
15,582
17,362
Depreciation and amortization
2,662
2,623
2,605
2,613
Stock-based compensation
1,935
2,092
2,096
1,740
Amortization of issuance costs on convertible senior notes
224
222
220
653
Non-cash investment income
703
102
-
-
Provision for inventory write-downs
787
761
768
863
Provision (benefit) for deferred income taxes
-
-
2,312
-
Loss on divestitures
-
-
0
-
Provision for credit losses
333
0
362
118
Fair value adjustments to contingent consideration obligations
-
-
-
0
Unrealized loss on equity investments
-
-
-535
-
Foreign currency transaction effect on income
-74
-71
97
-200
Accounts receivable
396
2,481
1,544
-3,896
Inventory and other deferred costs
543
1,392
418
6,805
Prepaid expenses and other assets
2,401
-1,038
-787
37
Accounts payable and other liabilities
-4,135
-2,340
-1,129
6,577
Accrued interest
1,078
-1,078
1,078
719
Net cash provided by operating activities
15,965
15,093
23,157
28,764
Purchases of short-term marketable securities
80,568
150,866
598,314
25,166
Purchases of property and equipment
2,313
2,783
1,777
2,281
Payments related to acquisitions, net of cash acquired
113
45
1,804
0
Proceeds from short-term marketable securities
71,916
140,573
585,070
-
Net cash used in investing activities
-11,078
-13,121
-16,825
-27,447
Proceeds from stock option exercises
776
2,952
2,166
1,585
Proceeds from issuance of convertible senior notes, net of issuance costs paid of 3,234
-
-
0
-
Deferred payments for acquisitions
95
0
0
0
Costs paid related to issuance of convertible senior notes-Convertible Senior Notes
-
-
0
-
Payment of withholding taxes in connection with net settlement of equity awards
17
460
1,216
0
Common stock cash dividend paid
5,716
5,711
4,537
4,535
Net cash used in financing activities
-5,052
-3,219
-3,587
-2,950
Effect of exchange rate changes on cash and cash equivalents
-61
-146
5
-50
Net (decrease) increase in cash and cash equivalents
-226
-1,393
2,750
-1,683
Cash and cash equivalents at beginning of period
26,851
28,244
25,494
25,610
Cash and cash equivalents at end of period
26,625
26,851
28,244
25,494
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net sales
$70,382K
Gross profit
$50,764K
Canceled cashflow
$19,618K
Net income
$17,050K
(-31.22%↓ Y/Y)
Depreciation and
amortization
$2,662K
(-48.81%↓ Y/Y)
Stock-based compensation
$1,935K
(-51.50%↓ Y/Y)
Accrued interest
$1,078K
Provision for inventory
write-downs
$787K
(-23.59%↓ Y/Y)
Provision for credit
losses
$333K
(-1.19%↓ Y/Y)
Amortization of issuance
costs on convertible...
$224K
Foreign currency
transaction effect on income
-$74K
(-126.52%↓ Y/Y)
Canceled cashflow
$33,714K
Cost of sales
$19,618K
Net cash provided by
operating activities
$15,965K
(-45.57%↓ Y/Y)
Canceled cashflow
$8,178K
Selling expense
$12,845K
Administrative expense
$7,526K
Other (income)
expense, net
-$3,349K
Finance expense
$2,647K
Regulatory and clinical
expense
$2,037K
Marketing expense
$1,563K
Research and development
expense
$1,472K
Process engineering
expense
$1,338K
Management information
systems expense
$937K
Net (decrease)
increase in cash and cash...
-$226K
(-114.42%↓ Y/Y)
Canceled cashflow
$15,965K
Proceeds from short-term
marketable securities
$71,916K
Proceeds from stock
option exercises
$776K
(-74.74%↓ Y/Y)
Accounts payable and
other liabilities
-$4,135K
(-230.80%↓ Y/Y)
Prepaid expenses and
other assets
$2,401K
(243.26%↑ Y/Y)
Non-cash investment
income
$703K
Inventory and other
deferred costs
$543K
(-84.28%↓ Y/Y)
Accounts receivable
$396K
(-92.53%↓ Y/Y)
Net cash used in
investing activities
-$11,078K
(46.40%↑ Y/Y)
Canceled cashflow
$71,916K
Net cash used in
financing activities
-$5,052K
(36.87%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$61K
(-106.71%↓ Y/Y)
Canceled cashflow
$776K
Purchases of short-term
marketable securities
$80,568K
(351.39%↑ Y/Y)
Purchases of property and
equipment
$2,313K
(-15.12%↓ Y/Y)
Payments related to
acquisitions, net of cash...
$113K
(18.95%↑ Y/Y)
Common stock cash
dividend paid
$5,716K
(-36.75%↓ Y/Y)
Deferred payments for
acquisitions
$95K
(-93.37%↓ Y/Y)
Payment of withholding
taxes in connection...
$17K
(-97.19%↓ Y/Y)
Buy us a coffee
LEMAITRE VASCULAR INC (LMAT)
LEMAITRE VASCULAR INC (LMAT)